Healthy
Conditions
Keywords
Cannabis, Marijuana, Cannabidiol, CBD, THC, Psychotic Disorders
Brief summary
Cannabis is the most commonly used illicit substance in the US and herbal cannabis consists of a number of cannabinoids including Δ-9 THC and CBD. This study will characterize the interactive effects of the two major components of cannabis i.e. Δ-9-THC and CBD.
Interventions
DRUGCannabidiol
Active Cannabidiol 5mg.
DRUGDelta-9-THC
Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint.
DRUGPlacebo
Placebo (about a quarter spoon of alcohol with no CBD).
Sponsors
Yale University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Exposed to Cannabis at least once in lifetime
Exclusion criteria
* Cannabis Naive
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Behavioral Measures | Baseline, +15, +80, +240 | Subjective effects, perceptual alterations, and cognitive effects will be assessed using visual analog scales, Positive and Negative Symptom Subscale (PANSS), Clinician Administered Dissociative States Scale (CADSS), Psychotomimetic States Inventory (PSI) and a neuro cognitive battery. |
Countries
United States
Outcome results
None listed